Introduction
Chemical Drug
Currently, the treatment for patients with Alzheimer’s disease (AD) is mainly symptomatic therapy. AD treatment commonly used drugs cannot curb the progress of dementia but can only delay the deterioration of cognitive function and improve brain function, therefore, these drugs cannot completely cure AD patients. Although pharmaceutical enterprises have maintained a high degree of enthusiasm for the development of AD new drugs, research and development activities of a new drug in this field have a very high failure rate, and in recent years, a series of new drugs entering Phase II or III clinical trials have failed. In addition, this disease lacks objective diagnostic criteria and biomarkers that can be used as clinical endpoints and efficacy criteria, which also poses a great challenge to the development of new drugs for AD. However, this disease is still one of the most active areas of new drug development. Moreover, considering the unmet clinical needs in the field of AD treatment, the FDA and other health administrations have provided strong support for the development of AD new drugs.
Classification of therapeutic drugs or targets in Alzheimer’s treatment
The well-defined risk factors for AD include inflammation, accumulation of reactive oxygen species (ROS), mitochondrial damage, genetic factors, cerebrovascular disease, brain trauma, and age-related sex hormone loss in men and women, and all of these risk factors can be targets for the development of new drugs for AD.
Currently, the treatment for patients with Alzheimer’s disease (AD) is mainly symptomatic therapy. AD treatment commonly used drugs cannot curb the progress of dementia but can only delay the deterioration of cognitive function and improve brain function, therefore, these drugs cannot completely cure AD patients. Although pharmaceutical enterprises have maintained a high degree of enthusiasm for the development of AD new drugs, research and development activities of a new drug in this field have a very high failure rate, and in recent years, a series of new drugs entering Phase II or III clinical trials have failed. In addition, this disease lacks objective diagnostic criteria and biomarkers that can be used as clinical endpoints and efficacy criteria, which also poses a great challenge to the development of new drugs for AD. However, this disease is still one of the most active areas of new drug development. Moreover, considering the unmet clinical needs in the field of AD treatment, the FDA and other health administrations have provided strong support for the development of AD new drugs.
Classification of therapeutic drugs or targets in Alzheimer’s treatment
The well-defined risk factors for AD include inflammation, accumulation of reactive oxygen species (ROS), mitochondrial damage, genetic factors, cerebrovascular disease, brain trauma, and age-related sex hormone loss in men and women, and all of these risk factors can be targets for the development of new drugs for AD.
Contact Info
Address:
45-1 Ramsey Road, Shirley, New York 11967, USA
New York
11967
United States
New York
11967
United States
Tel:
1-6316197922
Website:
https://www.creativebiomart.net/alzheimacy/therapeutics/chemical-drug/
Hours of operation
| From | To | From | To | From | To | ||
|---|---|---|---|---|---|---|---|
| Monday | Open | ||||||
| Tuesday | Open | ||||||
| Wednesday | Open | ||||||
| Thursday | Open | ||||||
| Friday | Open | ||||||
| Saturday | Open | ||||||
| Sunday | Open | ||||||
